CG Oncology (CGON) Competitors $30.21 +0.21 (+0.70%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CGON vs. ROIV, ASND, BPMC, RVMD, BBIO, LNTH, LEGN, ELAN, CYTK, and NUVLShould you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. CG Oncology vs. Roivant Sciences Ascendis Pharma A/S Blueprint Medicines Revolution Medicines BridgeBio Pharma Lantheus Legend Biotech Elanco Animal Health Cytokinetics Nuvalent Roivant Sciences (NASDAQ:ROIV) and CG Oncology (NASDAQ:CGON) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Do institutionals & insiders have more ownership in ROIV or CGON? 64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer ROIV or CGON? In the previous week, Roivant Sciences had 6 more articles in the media than CG Oncology. MarketBeat recorded 6 mentions for Roivant Sciences and 0 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.34 beat Roivant Sciences' score of 0.95 indicating that CG Oncology is being referred to more favorably in the news media. Company Overall Sentiment Roivant Sciences Positive CG Oncology Positive Do analysts recommend ROIV or CGON? Roivant Sciences presently has a consensus target price of $17.93, indicating a potential upside of 60.65%. CG Oncology has a consensus target price of $63.88, indicating a potential upside of 111.44%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88CG Oncology 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Is ROIV or CGON more profitable? Roivant Sciences has a net margin of 3,827.42% compared to CG Oncology's net margin of -10,642.98%. Roivant Sciences' return on equity of -14.65% beat CG Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences3,827.42% -14.65% -13.19% CG Oncology -10,642.98%-18.97%-15.36% Which has higher earnings & valuation, ROIV or CGON? Roivant Sciences has higher revenue and earnings than CG Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$124.79M65.10$4.35B$5.651.98CG Oncology$684K3,358.35-$48.61MN/AN/A Does the MarketBeat Community believe in ROIV or CGON? Roivant Sciences received 30 more outperform votes than CG Oncology when rated by MarketBeat users. However, 91.30% of users gave CG Oncology an outperform vote while only 77.27% of users gave Roivant Sciences an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5177.27% Underperform Votes1522.73% CG OncologyOutperform Votes2191.30% Underperform Votes28.70% SummaryRoivant Sciences beats CG Oncology on 9 of the 16 factors compared between the two stocks. Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGON vs. The Competition Export to ExcelMetricCG OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.30B$3.01B$5.39B$9.24BDividend YieldN/A1.89%5.37%3.99%P/E RatioN/A45.9289.1117.52Price / Sales3,358.35275.981,221.8479.25Price / CashN/A189.5243.6036.96Price / Book-15.574.045.014.72Net Income-$48.61M-$40.99M$117.81M$224.61M7 Day Performance2.03%2.03%2.03%1.55%1 Month Performance5.37%1.50%4.03%5.12%1 Year PerformanceN/A-1.33%26.78%21.25% CG Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGONCG Oncology1.266 of 5 stars$30.21+0.7%$63.88+111.4%N/A$2.30B$684,000.000.0061Positive NewsROIVRoivant Sciences3.643 of 5 stars$11.15+2.4%$17.93+60.8%+8.9%$8.12B$124.79M1.97860ASNDAscendis Pharma A/S3.47 of 5 stars$128.13-2.7%$192.07+49.9%-0.7%$7.78B$327.43M-15.86640Analyst RevisionNews CoverageBPMCBlueprint Medicines1.8377 of 5 stars$110.05+5.9%$122.72+11.5%+38.1%$6.99B$434.42M-52.16640RVMDRevolution Medicines4.4577 of 5 stars$40.29+1.0%$66.25+64.4%+49.1%$6.78B$11.58M-11.22250BBIOBridgeBio Pharma3.998 of 5 stars$33.79-0.9%$48.08+42.3%-1.5%$6.39B$9.30M-14.02400High Trading VolumeLNTHLantheus4.543 of 5 stars$91.47-0.1%$131.86+44.2%+77.2%$6.36B$1.50B15.22700LEGNLegend Biotech2.7233 of 5 stars$32.66+3.9%$80.62+146.8%-38.8%$5.96B$285.14M-34.381,800Analyst ForecastAnalyst RevisionNews CoverageGap UpELANElanco Animal Health4.3005 of 5 stars$12.03+0.1%$16.43+36.6%-17.6%$5.94B$4.42B30.069,300CYTKCytokinetics4.2922 of 5 stars$45.74-2.7%$83.64+82.9%-43.4%$5.40B$7.53M-8.50250Analyst ForecastAnalyst RevisionNews CoverageNUVLNuvalent1.9311 of 5 stars$75.84-0.2%$112.36+48.2%+3.8%$5.39BN/A-21.8640 Related Companies and Tools Related Companies Roivant Sciences Competitors Ascendis Pharma A/S Competitors Blueprint Medicines Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors Lantheus Competitors Legend Biotech Competitors Elanco Animal Health Competitors Cytokinetics Competitors Nuvalent Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGON) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
